Oct 30, 2020 / NTS GMT
Philip Toleikis - Sernova Corp. - President & CEO
I'm Dr. Philip Toleikis, President and CEO of Sernova Corp. Sernova is a publicly traded, clinical-stage, regenerative medicine therapeutics company. Type 1 diabetes is our first clinical application and we have an active Phase II clinical trial ongoing at the University of Chicago that I will be speaking about today.
In addition, we have two other programs that we have strong proof-of-concept data pre-clinically. These include hemophilia A, which is a chronic bleeding disorder in patients and also, hypothyroid disease. And this is a treatment for patients that are having their thyroid gland removed and have to be on chronic medications every day for the rest of their lives.
Our approach involves a -- three technologies that we put together in a very simple kind of approach. The first is a Cell Pouch, which is a medical device, about three-quarters the size of a business card that is placed deep under the skin and it forms an organ-like environment for therapeutic cells after a couple of weeks. We then place therapeutic cells, which then
Sernova Corp At TSX Life Sciences Investor Day Transcript
Oct 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers